Shire and Noven Pharmaceuticals have announced the voluntary
withdrawal of a limited amount of Attention Deficit Hyperactivity
Disorder (ADHD) transdermal patches following reports of a
mechanical problem when applying the patch.
Shire Pharmaceuticals has acquired exclusive development rights to
a new transdermal patch product for Attention-Deficit/Hyperactivity
Disorder (ADHD), adding a further novel product to its ADHD